EGF and atrial fibrillation: The AF-FLOW Global Registry also gave physicians the liberty to treat EGF-identified sources in a way they saw fit, and patients were not randomized to have all sources with an SAC of ≥ 26.5% ablated or left unablated as they were in the FLOW-AF study arms.